ECE2022 Rapid Communications Rapid Communications 6: Endocrine-Related Cancer (8 abstracts)
Oncological patients with endocrine complications after immunotherapy with checkpoint inhibitors present longer progression free and overall survival
Stavroula A Paschou 1 , Michael Liontos 2 , Evangelos Eleftherakis-Papaiakovou 2 , Katerina Stefanaki 1 , Christos Markellos 2 , Konstantinos Koutsoukos 2 , Flora Zagouri 2 , Theodora Psaltopoulou 2 & Meletios-Athanasios Dimopoulos 2
1Endocrine Unit and Diabetes Center, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; 2Hematology and Oncology Unit, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
Aim: To investigate the association of endocrine complications after ICIs immunotherapy with progression free survival (PFS) and overall survival (OS) in a large single-center oncological cohort.
Patients and methods: In total, 351 patients were included in the analysis, 248 men (70.7%) and 103 women (29.3%). The median age was 66 years. Patients had a variety of cancer types, namely bladder cancer (131, 37.3%), renal cancer (89, 25.4%), lung cancer (74, 21.1%), ovarian cancer (22, 6.3%) and other types of cancer (35, 10%). The majority (314, 89.4%) were classified as stage IV, while 10.6% (37) were classified as stage III. Most of the patients received immunotherapy with anti-PD1 agents (262, 74.6%) and the rest with anti-PD-L1 agents (89, 25.4%). Kaplan-Meier estimates were used to describe and visualize the effect of categorical variables on OS and PFS. Survival analysis was performed by Kaplan-Meier curves and survival differences between groups were estimated using the log-rank test. The estimation of the prognostic value of several variables with patients’ survival was made by Cox regression models.
Results: In total, 68 (19.4%) of patients presented an endocrine complication after immunotherapy with ICIs. Specifically, 66 (18.8%) had thyroid dysfunction, 1 patient presented hypophysitis (0.3%) and 1 patient had combination of thyroid dysfunction and hypophysitis (0.3%). Patients with an endocrine complication had mPFS of 15 months (95% CI 11.0-18.9 months), while in those without endocrine complication mPFS was 7 months (95% CI 6.1-7.9 months, P<0.001). Similarly, median OS (mOS) was statistically significant lower in the patients’ group without endocrine complication. In fact, mOS was 51 months (95% CI 39.3-62.7 months) for these patients. These results retained significance in terms of longer PFS (1.812, 95% CI 1.270-2.586) and OS (1.805, 95%CI 1.088-2.994) after multivariate analysis.
Conclusions: ICIs endocrinopathies may be a positive predictor of immunotherapy response.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more